多克隆抗体疗法:分析创新和解决异质性挑战的监管前景
Sunil Kumar1, Aurora Tini1, Sara Tengattini1
1Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
Analytical chemistry
|February 19, 2026
概括
多克隆抗体 (pAbs) 与单克隆抗体 (mAbs) 相比具有优势,但面临着特征化的挑战. 新的高分辨率分析方法能够更好地控制pAb疗法的质量,改善其临床开发.
科学领域:
- 免疫学和生物技术
- 分析化学 分析化学
- 制药科学 制药科学
背景情况:
- 多克隆抗体 (pAbs) 对于适应性免疫至关重要,并作为静脉注射免疫球蛋白 (IVIg) 用于治疗.
- 与单克隆抗体 (mAbs) 相比,pAbs提供了生产优势,但它们的异质性带来了分析和监管障碍.
- 目前的分析方法缺乏充分描述pAb关键质量属性 (CQA) 的分辨率.
研究的目的:
- 为突出pAb特征的高分辨率分析技术的进步.
- 讨论评估pAb CQAs对于治疗开发的重要性.
- 探索基于pAb的治疗方法的不断变化的监管环境.
主要方法:
- 审查最近的色谱和质谱技术的进展.
- 专注于分析策略来评估pAb的结构完整性,分子大小,子类组成和多克隆性.
- 审查监管框架和对标准化分析标准的需求.
主要成果:
- 高分辨率的分析技术能够对pAb CQAs进行深入的表征.
- 这些方法有助于评估关键参数,以确保产品质量和一致性.
- 不断发展的监管框架支持对pAbs.标准化分析标准的开发.
结论:
- 将先进的分析能力与监管期望相结合,可以增强pAb的治疗开发.
- 改进的表征将使pAbs能够在临床实践中更有效地补充mAbs.
- 标准化分析方法是确保pAb疗法的安全性,有效性和一致性的关键.
相关概念视频
01:31Hybridoma Technology
13.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370